经络氧疗法联合利培酮治疗难治性精神分裂症对照研究

A Control Study of the Meridian Oxygen Therapy Combined with Risperdal in Refractory Schizophrenia

目的探讨经络氧疗法联合利培酮(维思通)治疗难治性精神分裂症的疗效和安全性。方法按入院时间先后顺序共纳入72例难治性精神分裂症患者,将其随机分成经络氧联合利培酮组(研究组,36例)和单用利培酮组(对照组,36例)。有12例患者脱落,实际观察60例,研究组31例,对照组29例。两组患者均给予利培酮治疗,而研究组另加用经络氧疗法,疗程12周。在治疗前及治疗2、3、4、6、8、12周末采用阳性与阴性症状量表(PANSS)、副反应量表(TESS)分别评定疗效和副作用。结果研究组治疗后痊愈7例,显著进步11例,进步7例,无效6例;对照组痊愈4例,显著进步7例,进步5例,无效13例,两组患者疗效间差异有统计学意义(P<0.05);研究组和对照组总有效率分别为80.6%和55.2%,差异有统计学意义(χ2=4.49,P=0.034)。治疗第2周末,研究组PANSS阴性症状分与治疗前比较,差异即有统计学意义(P<0.01);而对照组从治疗第3周末开始,阴性症状分与治疗前比较差异才有统计学意义(P<0.01)。治疗结束后两组TESS评分间差异无统计学意义(P>0.05),但研究组锥体外系反应静坐不能、震颤、性功能减退的发生率显著低于对照组,鼻塞的发生率显著高于对照组,差异均有统计学意义(P<0.05)。结论经络氧疗法应用于难治性精神分裂症可以提高利培酮的疗效,能较早缓解阴性症状,且安全性好,是探索治疗难治性精神分裂症的一个新途径。

Objective To investigate the safety and efficacy of meridian oxygen therapy combined with Risperdal in the treatment of refractory schizophrenia（RS）.Methods Seventy-two RS patients were randomized,according to chronological order of admission to hospital,into groups study（n=36） and control（n=36）.Both were given risperdal treatment,the study group given additional meridian oxygen therapy,for 12 weeks.The effectiveness and side effects were evaluated,by Positive and Negative Symptom Scale（PANSS） and Treatment Emergency Symptom Scale,before treatment or at the ends of weeks 2,3,4,6,8.Twelve patients missed follow-up,60 were observed actually（31 in study group,29 in control）.Results After treatment,7 patients were cured,obvious effectiveness was noted in 11,effectiveness in 7,ineffectiveness in 6 in study group,and 4,7,5,15,respectively,in control group,the difference was significant（P〈0.05）.The total effective rates of groups study and control were 80.6%,55.2%,respectively,the difference was significant（P〈0.01）.In control group,the negative symptom score at the end of weeks 3 began to differ significantly from that before treatment.No significant difference was noted in TESS score between 2 groups（P〉0.05）,the incidence of extrapyramidal system reaction akathisia,tremor,sexual dysfunction was lower,the incidence of nasal obstruction higher in study group than in control,the difference was significant（P〈0.05）.The total effective rate of groups study and control were 80.6%,55.2%,respectively,the difference was significant（χ^24.49,P=0.034）.In study group,PANSS at 2nd weekend was significantly different from that before treatment（P〈0.01）,but in control group,significant difference began to be noted only at 3rd weekend（P〈0.01）.There was not significant difference in TESS between 2 groups after treatment（P〉0.05）,but the incidence of extrapyramidal system reaction akathisia,tremor,sexual dysfunction was significantly lower,that of nasal obstruction higher in study group than in control（P〈0.05）.Conclusion In treatment of RS,meridian oxygen therapy,improving the efficacy of risperdal and alleviating negative symptoms earlier with good safety,is a new way to explore RS treatment.